‹
›
This content requires a premium subscription.
Please
log in
or
subscribe
to continue.
The Beacon
Novel Agent Enfortumab, a Nectin-4 Inhibitor, for Transitional Cell Carcinoma of the Bladder: Highlights from ASCO 2018 (BMIC-049)
30
00:00:00
/ 00:01:58
30